CN114364372A - 包含环孢菌素和薄荷醇的纳米乳液眼用组合物及其制备方法 - Google Patents

包含环孢菌素和薄荷醇的纳米乳液眼用组合物及其制备方法 Download PDF

Info

Publication number
CN114364372A
CN114364372A CN202080062721.9A CN202080062721A CN114364372A CN 114364372 A CN114364372 A CN 114364372A CN 202080062721 A CN202080062721 A CN 202080062721A CN 114364372 A CN114364372 A CN 114364372A
Authority
CN
China
Prior art keywords
amount
castor oil
less
cyclosporin
ophthalmic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080062721.9A
Other languages
English (en)
Chinese (zh)
Inventor
李俊晔
慎允宰
徐贤源
金大勋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taejoon Pharm Co Ltd
Original Assignee
Taejoon Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taejoon Pharm Co Ltd filed Critical Taejoon Pharm Co Ltd
Publication of CN114364372A publication Critical patent/CN114364372A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080062721.9A 2019-09-09 2020-09-04 包含环孢菌素和薄荷醇的纳米乳液眼用组合物及其制备方法 Pending CN114364372A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20190111776 2019-09-09
KR10-2019-0111776 2019-09-09
PCT/KR2020/011977 WO2021049825A1 (ko) 2019-09-09 2020-09-04 사이클로스포린 및 멘톨 함유 나노 에멀젼 점안 조성물 및 그의 제조 방법

Publications (1)

Publication Number Publication Date
CN114364372A true CN114364372A (zh) 2022-04-15

Family

ID=74867274

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080062721.9A Pending CN114364372A (zh) 2019-09-09 2020-09-04 包含环孢菌素和薄荷醇的纳米乳液眼用组合物及其制备方法

Country Status (8)

Country Link
US (1) US12576126B2 (cg-RX-API-DMAC7.html)
EP (1) EP4029493A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022548221A (cg-RX-API-DMAC7.html)
KR (2) KR102273481B1 (cg-RX-API-DMAC7.html)
CN (1) CN114364372A (cg-RX-API-DMAC7.html)
CA (1) CA3149270A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550500A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021049825A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023190283A1 (ja) * 2022-03-28 2023-10-05 中外製薬株式会社 ポリオキシエチレン構造を含む油性成分を含有する化合物製剤
IL294896B1 (en) * 2022-07-20 2026-06-01 LYOTROPIC DELIVERY SYSTEMS Ltd Topical administration of cyclosporine to the eye

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012015211A2 (ko) * 2010-07-30 2012-02-02 주식회사종근당 사이클로스포린 에이 함유 점안제 조성물
CN105307668A (zh) * 2013-05-20 2016-02-03 株式会社泰俊制药 包含环孢菌素的纳米乳剂滴眼剂组合物和制备其的方法
CN105726479A (zh) * 2016-03-24 2016-07-06 北京茗泽中和药物研究有限公司 环孢素眼用乳剂
US20190224120A1 (en) * 2016-10-12 2019-07-25 Ps Therapies Ltd Drug vehicle compositions and methods of use thereof
CN110090294A (zh) * 2019-04-09 2019-08-06 嘉兴市爵拓科技有限公司 具有改善的干燥保护和保留的眼用组合物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635796B2 (en) 1990-03-16 2003-10-21 Sevenson Environmental Services, Inc. Reduction of leachability and solubility of radionuclides and radioactive substances in contaminated soils and materials
KR0167613B1 (ko) 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
KR20020011985A (ko) * 1999-05-07 2002-02-09 파르마솔 게엠베하 액상 및 고체상 지질 혼합물에 기초한 지질입자들 및 그의제조방법
CA2426164C (en) 2001-06-27 2009-08-11 Nokia Corporation Method and system for bearer authorization in a wireless communication network
AU2002357604A1 (en) 2001-12-21 2003-07-09 Senju Pharmaceutical Co., Ltd. Eye drops
PT1487416E (pt) 2002-03-26 2010-01-25 Teva Pharma Micropartículas de fármacos
CN1232539C (zh) 2002-05-10 2005-12-21 刘云清 有机药物与倍他环糊精衍生物的配合物及其制备方法
AU2004212989A1 (en) * 2003-02-20 2004-09-02 Teva Pharmaceutical Industries Ltd. Menthol solutions of drugs
US20070008894A1 (en) 2004-10-19 2007-01-11 Idt Corporation Telecommunications-based link monitoring system
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
KR100669510B1 (ko) 2005-08-17 2007-01-16 보람제약주식회사 사이크로스포린을 함유한 나노 에멀젼 농축액 조성물 및 그제조방법
CN101244256A (zh) * 2007-02-16 2008-08-20 中国科学院上海药物研究所 一种环孢菌素a眼用微/亚微乳原位凝胶制剂及其制备方法
EP3078385A1 (en) * 2010-05-25 2016-10-12 Allergan, Inc. Cyclosporin emulsions
KR20130100290A (ko) * 2010-08-30 2013-09-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 협착성 병변을 위한 전단 제어 방출 및 혈전 용해 치료법
US8455991B2 (en) 2010-09-24 2013-06-04 Stats Chippac Ltd. Integrated circuit packaging system with warpage control and method of manufacture thereof
WO2013008714A1 (ja) * 2011-07-08 2013-01-17 ロート製薬株式会社 眼科用水性組成物
KR101211902B1 (ko) 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
US10963928B2 (en) 2014-08-21 2021-03-30 Stubhub, Inc. Crowdsourcing seat quality in a venue
DK3006045T3 (en) * 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
KR20170032808A (ko) * 2015-09-15 2017-03-23 주식회사 엘지생활건강 멘톨 또는 멘톨 유도체를 포함하는 용해성 미세바늘 패치
CA3285799A1 (en) * 2016-10-12 2025-11-29 Ps Therapy, Inc. Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
WO2019111917A1 (ja) * 2017-12-07 2019-06-13 ライオン株式会社 水性眼科用組成物及びエマルション粒子の微粒化方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012015211A2 (ko) * 2010-07-30 2012-02-02 주식회사종근당 사이클로스포린 에이 함유 점안제 조성물
CN105307668A (zh) * 2013-05-20 2016-02-03 株式会社泰俊制药 包含环孢菌素的纳米乳剂滴眼剂组合物和制备其的方法
CN105726479A (zh) * 2016-03-24 2016-07-06 北京茗泽中和药物研究有限公司 环孢素眼用乳剂
US20190224120A1 (en) * 2016-10-12 2019-07-25 Ps Therapies Ltd Drug vehicle compositions and methods of use thereof
CN110090294A (zh) * 2019-04-09 2019-08-06 嘉兴市爵拓科技有限公司 具有改善的干燥保护和保留的眼用组合物

Also Published As

Publication number Publication date
EP4029493A4 (en) 2023-10-04
KR20210030215A (ko) 2021-03-17
WO2021049825A1 (ko) 2021-03-18
KR102638866B1 (ko) 2024-02-21
KR102273481B1 (ko) 2021-07-06
KR20210084389A (ko) 2021-07-07
EP4029493A1 (en) 2022-07-20
PH12022550500A1 (en) 2023-10-18
US20240041974A1 (en) 2024-02-08
JP2022548221A (ja) 2022-11-17
US12576126B2 (en) 2026-03-17
CA3149270A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
KR102133381B1 (ko) 사이클로스포린을 함유하는 나노에멀젼 점안 조성물 및 그의 제조 방법
JP5736635B2 (ja) ドライアイ治療剤
CN101674804A (zh) 包含前列腺素的眼科用水包油型乳剂
WO2010141591A1 (en) Omega-3 oil containing ophthalmic emulsions
EP3727337A1 (en) Microemulsion for opthalmic drug delivery
CN108348468A (zh) 具有生物活性亲脂性化合物的聚乙二醇化脂质纳米粒
AU2010256679B2 (en) Therapeutic ophthalmic emulsions
KR20160144507A (ko) 고농도 올로파타딘 안과용 조성물
CN103764120A (zh) 聚乙二醇15羟基硬脂酸酯制剂
EP4013443A1 (en) In-situ gel containing cyclosporine micelles as sustained ophthalmic drug delivery system
CN112516084A (zh) 含有环孢素胶束的原位凝胶作为缓释眼科药物递送系统
US12576126B2 (en) Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof
KR102365008B1 (ko) 디쿠아포솔을 포함하는 점안 조성물
US20240180826A1 (en) Opthalmic Compositions for Dry Eye Treatment and Methods of Manufacture of the Same
Lallemand et al. Emulsions for topical eye delivery: state of the art and future perspectives
CN110022856B (zh) 用于降低眼压的眼用组合物
CN112294761A (zh) 一种难溶性药物的眼用胶束制剂
Singh et al. Adverse effects of antiglaucoma medications: pathophysiology and novel drug delivery strategies for mitigation
Rupenthal et al. Ocular drug delivery
CN112839641A (zh) 眼科用组合物
KR101510764B1 (ko) 사이클로스포린 함유 안약 조성물 및 그 제조방법
US20240009124A1 (en) Ophthalmic Suspension Base having a Micro-fluidized Positively Charged Nanoparticle
WO2024241345A1 (en) Ophthalmic suspension composition of brinzolamide and latanoprost
AU2014250656B2 (en) Omega-3 oil containing ophthalmic emulsions
McCann Advances and challenges in topical ocular medications

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20220415